Developmental funds are requested to recruit faculty level scientists in areas of strategic need, to support pilot projects that allow Fox Chase Cancer Center scientists to pursue innovative ideas in high priority research areas, and to support technology and methodology development projects related to the Center's discovery mission and strategic objectives. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer reviewed funding within 24 months of their appointment Of that amount $5.1 million was garnered by investigators directly leveraging developmental funds. Also, this class competed successfully for a further $1.6 million in competitive foundation support. During the last CCSG cycle, pilot project funds were utilized in the second, fifth and sixth years to support potential high-impact projects, largely from established investigators. The 12 funded projects have already produced two funded grants and seven publications. During the past CCSG cycle, the Center provided start up support for a High Throughput Screening Facility that has become one of the 16 established shared facilities. In the present CCSG application we seek partial support for the 25 new investigators identified as necessary to address the critical mass needs of the Center's five existing programs over the next CCSG cycle. This request represents less than 25% of the average cost of supporting a new investigator. We also seek support for partial funding for four translational pilot projects per year. These CCSG funds will be matched by institutional funds. Finally, we seek partial funding for technology developments and informatics initiatives in support of the Center's Institute for Personalized Medicine. All of these developmental funds are considered vital to achieving the discovery objectives outlined in the Center's Strategic Plan.
Development funds are critical for use in recruiting faculty level scientists and to support pilot projects at Fox Chase Cancer Center allowing scientists to pursue innovative ideas in high priority research areas. These funds are also necessary to promote emerging technologies used in cancer research.
|Peri, Suraj; Caretti, Elena; Tricarico, Rossella et al. (2017) Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget 8:17628-17642|
|Reese, Jennifer Barsky; Bober, Sharon L; Daly, Mary B (2017) Talking about women's sexual health after cancer: Why is it so hard to move the needle? Cancer 123:4757-4763|
|Christian, Allison H; O'Malley, Denalee; Barac, Ana et al. (2017) Cardiovascular risk and communication among early stage breast cancer survivors. Patient Educ Couns 100:1360-1366|
|Jiang, Pengtao; Li, Yueran; Poleshko, Andrey et al. (2017) The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine 22:28-43|
|Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038|
|Heckman, Carolyn J; Kloss, Jacqueline D; Feskanich, Diane et al. (2017) Associations among rotating night shift work, sleep and skin cancer in Nurses' Health Study II participants. Occup Environ Med 74:169-175|
|Cheung, Mitchell; Testa, Joseph R (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6:270-278|
|Gerson, James N; Skariah, Sam; Denlinger, Crystal S et al. (2017) Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 26:531-540|
|Kruger, Warren D (2017) Cystathionine ?-synthase deficiency: Of mice and men. Mol Genet Metab 121:199-205|
|Jaffe, Eileen K (2017) New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab 121:289-296|
Showing the most recent 10 out of 1165 publications